1. Introduction {#sec1}
===============

Uterine cancer is the sixth most common cancer in women in the world and the fourth most common cancer in Europe. It is also the second most common cancer among gynecological cancers after cervical cancer in the world and first in Europe \[[@B1]\]. The management of endometrial cancer is complex and it is based on surgical treatment, radiotherapy, chemotherapy, and hormonal therapy. A recommended and routine surgical procedure is the total abdominal hysterectomy with bilateral salpingooophorectomy \[[@B2]\]. The role of pelvic lymphadenectomy has not been definitively established and remains controversial \[[@B3]\]. Depending on the stage of cancer, exclusive observation, teleradiotherapy, brachytherapy, a combination therapy involving both of these methods, or chemotherapy are used after surgery \[[@B2]\].

In general, no supplementary treatment \[[@B2]\] is used in the low-risk group (IA, G1, G2, and endometrioid type). Literature analysis indicates no benefit in overall survival from complementary radiotherapy \[[@B4]--[@B8]\]. There are also no new, large randomized trials comparing complementary brachytherapy with exclusive observation in this group of patients. The decision regarding complementary treatment or follow-up in other patients with FIGO (International Federation of Gynecology and Obstetrics) IA is usually based on the presence of a number of factors, which are considered unfavorable prognosis. These include the following: age \> 70 years, histopathological type II or mixed (according to Bokhman), low tumor descent, tumor mass \> 2 cm, low uterine segment involvement (LUSI), and histopathological grade G3 \[[@B2]\]. There is even more controversy about patients with FIGO IB---there are no studies comparing exclusive surveillance with independent brachytherapy in this group of patients. Treatment usually depends on the presence of risk factors, the hospital\'s own experience, and the patient\'s preference. In this study, we performed a one-sided, comparative retrospective analysis of patients with early-stage endometrial cancer treated with complementary brachytherapy or postoperative follow-up.

2. Material and Methods {#sec2}
=======================

2.1. Characteristics of Patients {#sec2.1}
--------------------------------

The retrospective analysis included 178 patients with histopathologically confirmed invasive endometrial cancer in the first stage of FIGO clinical stage, treated by brachytherapy or subjected to a control study in 1989--2013. All patients were after total abdominal hysterectomy with bilateral salpingooophorectomy. Node dissection was optional. All patients were treated with a radical premise. The patients were divided according to the scheme shown in [Figure 1](#fig1){ref-type="fig"} into two groups:Treated group: who received adjuvant brachytherapyObserved group: who used only observation.

Then, depending on clinical and histopathological factors, the two groups were divided according to the scheme shown in [Figure 1](#fig1){ref-type="fig"} into patients with low and medium risk.

There were 49 low-risk and 59 medium-risk patients in the treated group and 32 low-risk patients and 38 medium-risk patients in the observed group ([Table 1](#tab1){ref-type="table"}).

2.2. Treatment {#sec2.2}
--------------

Patients from both groups had undergone uterine abduction with pelvic lymphadenectomy or no lymphadenectomy. Patients in the treated group were irradiated by HDR (High Dose Rate) brachytherapy using Ir192 source. The treatment was started from the placement of a single-tube cylindrical applicator into the vagina and an X-ray examination to plan the treatment. Treatment planning was to determine the source stops and stopping time of the source in the applicator to cover with the prescribed isodose the upper 1/3 part of the vaginal mucosa at a depth of 5 mm. The dose was also calculated at the ICRU (International Commission on Radiation Units and Measurements) of the bladder and rectum and the maximum dose in the vaginal mucosa. Median fractional dose was 7.5 (6--8) Gy and total dose 30 (15--32) Gy. Most 3-4 fractions were used at weekly intervals.

Patients undergoing exclusive follow-up and postbrachytherapy patients were assigned for a follow-up visit every three months during the first two years and then every six months and every five years. The primary outcome measure was the 3-, 5-, and 10-year OS, DFS, and LRFS rates, depending on the type of follow-up and prognosis. The second outcome was identification of risk factors of tumor recurrence. Statistical analysis was performed with the Kaplan-Meier method along with the log-rank test.

3. Results {#sec3}
==========

3.1. Overall Survival (OS) {#sec3.1}
--------------------------

Patients included in the study were followed for an average of 67,46 ± 45,27 months after treatment (over 6.5 years). In the treated group, the mean follow-up was 48.74 ± 20.15 months (over 4 years). In the observed group the mean follow-up was longer, 96.35 ± 56.86 months (8 years). The median follow-up time in both groups was 58.88 months (range 0--316.93 months), with 54.52 months (range 0--90.13) in the treated group and 87.22 months in the observed group (25.63--316,93 months).

In the treated group of 108 patients 9.3% (10/108) died during the observation period. In the observed group of 70 patients, 7.1% (5/70) died during the observation period.

There were no statistically significant differences in overall survival between the treated and the observed group (*p* \> 0.05) ([Figure 2](#fig2){ref-type="fig"}). In the treated group, there was a statistically significant difference in overall survival between the low- and the medium-risk patients (*p* = 0.018). There was no statistically significant difference between low risk and medium risk in the observed group (*p* \> 0.05) ([Figure 3](#fig3){ref-type="fig"}). In addition, among the low-risk and medium-risk patients, no statistically significant differences in overall survival between the treated and observed group (*p* \> 0.05) were reported; 3-, 5-, and 10-year OS in groups and subgroups are shown in [Table 2](#tab2){ref-type="table"}.

3.2. Disease-Free Survival (DFS) {#sec3.2}
--------------------------------

In the treated group, 4 patients (4%) were documented for recurrence during the follow-up period. The median time to recurrence was 47.54 ± 20.91 months, the median time to recurrence was 53.37 months (range 0--90 months). Two patients (2%) had a recurrence at the vaginal stump area, and in the remaining 2 patients there were distant metastases to the lung and lymph nodes of the abdominal cavity. Both local recurrences occurred among medium-risk patients. Distant metastases were documented among patients with low and medium risk. In the observed group, the mean disease-free survival was 95.4 ± 58.05 with the median 87.77 months (range 13--320 months). During the whole period of observation a recurrence of the tumor was observed in 5 patients (7%), in 4 (6%) it was a local recurrence, and in 1 patient (1%) it was lung metastases. Three patients with localized recurrence were among the low-risk patients, one among the medium-risk patients. A distant recurrence was documented in the medium-risk group.

There were no statistically significant differences in disease-free survival between the treated group and the observed group (*p* \> 0.05) ([Figure 4](#fig4){ref-type="fig"}). No significant difference in disease-free survival between patients with low and medium risk (*p* \> 0.05) was observed in either group ([Figure 5](#fig5){ref-type="fig"}). Among the low-risk and medium-risk patients, no statistically significant differences in disease-free survival between the treated and observed group (*p* \> 0.05) were reported. Three-, 5- and 10-year-old DFS in the groups and the subgroups are presented in [Table 2](#tab2){ref-type="table"}.

3.3. Local Relapse-Free Survival (LRFS) {#sec3.3}
---------------------------------------

Local recurrences occurred in 2 patients (2%) in the treated group and 4 (6%) in the observed group (*p* \> 0.05). In patients with a low risk of local recurrence none occurred in the treated group and 9% occurred in the observed group. Among the medium-risk patients, the percentage of local recurrences in both groups was similar (3%). There were no statistically significant differences in LRFS between patients in the treated group and the observed group (*p* \> 0.05) ([Figure 6](#fig6){ref-type="fig"}). None of the groups showed statistically significant differences in the local relapse-free survival between low- and medium-risk patients ([Figure 7](#fig7){ref-type="fig"}). In addition, among the low-risk and medium-risk patients, no statistically significant differences in local relapse-free survival between the treated and observed group (*p* \> 0.05) were reported; 3-, 5-, and 10-year-old LRFS in groups and subgroups are shown in [Table 2](#tab2){ref-type="table"}.

3.4. Impact of Risk Factors {#sec3.4}
---------------------------

In the treated and observed groups the influence of particular factors on the prognosis was analyzed. There was a statistically significant effect of age (\<70) on OS and the clinical stage on DFS. Other factors alone did not affect survival (*p* \> 0.05). The results are presented in [Table 3](#tab3){ref-type="table"}.

4. Discussion {#sec4}
=============

Literature analysis in the low-risk group (Ia-G1, G2, and endometrioid type) indicates no benefit in overall survival from complementary brachytherapy \[[@B2]\]. In many cases, exclusive observation in early endometrial cancer seems to be sufficient. Very good results were obtained using also brachytherapy \[[@B10], [@B11], [@B9]\]. A comparison of exclusive observation and brachytherapy conducted by Sorbe et al. \[[@B12]\] as well as the analysis of own material indicates no statistically significant difference in the recurrence rate.

Controversy raises the value of complementary treatment in the case of FIGO IB or FIGO IA, which coincides with age-related factors such as age \> 70 years, histopathological type II or mixed (according to Bokhman), low tumor descent, tumor size \> 2 cm, LVSI, and histopathological grade G3. Depending on the studies in which they were evaluated and the risk factors for which they were classified in the prognostic groups, patients with recurrence risk factors were usually classified as either medium or high risk \[[@B4]--[@B6]\]. In the analyzed study, the medium-risk group consisted of FIGO IA patients with risk factors for recurrence (age \> 70 years, histopathological type II or mixed, low tumor descent, tumor size \> 2 cm, and histopathological grade G3) or patients with FIGO IB, irrespective of the presence of other factors.

Studies show that in this group of patients after the use of adjuvant brachytherapy the rate of recurrence in the vagina is very low and the rate of survival free from recurrence and overall survival is high, even when the total dose is lower than our analysis \[[@B13], [@B14], [@B15]--[@B17], [@B18], [@B19], [@B22]--[@B21]\] ([Table 4](#tab4){ref-type="table"}). There are no large trials comparing independent brachytherapy and observation in the medium-risk group or high-intermediate-risk group. Nevertheless, PORTEC has shown that 72% of recurrences occur in the vagina, and, in GOG-99, 77.8% of all failures occurred in the vagina \[[@B4]--[@B6]\]. The analysis of own material in the medium-risk group indicates the lack of benefits from adjuvant brachytherapy in OS, DFS, and LRFS.

Analysis of all groups confirms the possible effect of brachytherapy on the reduction of local recurrence rate (6% in the observed group versus 2% in the treated group, NS). This is particularly evident among low-risk patients (9% in the observed group versus 0% in the treated group, NS). Unfortunately, the relapse rate in this study was too low to obtain statistical significance.

Many studies indicate deterioration of prognosis with the depth of uterine muscle invasion. Dunn et al. \[[@B27]\] in Cox\'s univariate analysis indicate that the degree of infiltration of muscle is an independent risk factor for a deterioration of the prognosis (*p* = 0.004). Some authors diminish the role of the depth of infiltration. Aristizabal et al. \[[@B28]\] did not show differences in 5-OS between FIGO IA and IB patients. In the analyzed group only the treated group showed a deterioration of relapse-free survival without effect on overall survival (*p* = 0.047). Among the other factors, only the elderly were affected by a deterioration of survival, which is understandable because of the likely higher incidence of coexisting diseases in this age group. The effects of advanced age on the percentage of relapses were not reported. Studies show that older age favors deterioration of overall survival by 12%, relapse-free survival by 11%, and local recurrence by 8% \[[@B27], [@B29]\]. Similarly in the study of Arenas et al. \[[@B30]\] age \< 75 years and myometrial invasion ≤ 50% are predictors of a good outcome in endometrial cancer.

Many studies indicate an effect on prognosis of other risk factors such as tumor localization, tumor size \> 2 cm, Bokhman tumor type II, or G3 grade \[[@B28], [@B30]--[@B33]\]. While the effect of G3 grade or some type of histopathologic type II tumor type does not leave room for doubt, the role of tumor size or location is questionable among many researchers \[[@B34], [@B35]\]. No statistically significant effects of the above described risk factors on OS or DFS were reported in the study group. These results may, however, be associated with a small number of patients with particular risk factors and a low number of recurrences and deaths in the analyzed group of patients.

The limitation of the study was a retrospective analysis of patients. This analysis included more than 10 years of follow-up, during which indications for adjuvant therapy were evolved to reduce brachytherapy. This causes an unequal distribution of some risk factors in both groups; however, a small percentage of them does not seem to affect the final outcomes. Another reason was the tendency to select patients depending on the type of risk factors like LUSI, size of tumor, and histopathologic type and grade.

5. Conclusion {#sec5}
=============

Among patients with early endometrial cancer the prognosis is good, regardless of treatment administered. Brachytherapy effects on OS, DFS, and LRFS have not been demonstrated. Based on the above data, patients from the low- and intermediate-risk groups should be observed after surgical treatment. The use of brachytherapy in the low-risk group (FIGO IA, G1, 2, and no risk factors) may reduce the incidence of localized recurrences in the vagina although, due to the small percentage of relapses, these differences are not statistically significant. In the medium-risk group (IB and/or risk factors) there was no reduction in the rate of relapse after brachytherapy. Because of the lower OS in the medium-risk group, compared to the low-risk group, further research is needed to find new treatments that will improve the outcome.

The clinical stage of FIGO IB increases the risk of recurrence, although it has no effect on survival. The older age deteriorates overall survival, without affecting disease-free survival. Factors such as tumor size, low tumor location, G3, or Bokhman type II do not affect prognosis, although due to the low rate of relapses and deaths, as well as the small number of patients with particular factors, this issue requires further investigation on a larger group of patients.
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###### 

Characteristics of patients.

  Demographical or clinical risk factor   Treated group, *n* = 108   Observed group *n* = 70
  --------------------------------------- -------------------------- -------------------------
  Age of patients: median (range)         65 (47--90) years          66 (46--90) years
  FIGO:                                                               
   IA                                     92 (85%)                   59 (84%)
   IB                                     16 (15%)                   11 (16%)
  Number of risk factors                                              
   0                                      53 (49%)                   35 (50%)
   1                                      51 (47%)                   29 (41%)
   2                                      4 (4%)                     6 (9%)
  Type of risk factors                                                
   LUSI                                   9 (8%)                     2 (3%)
   Size of tumor \> 2 cm                  11 (10%)                   2 (3%)
   Histopathologic type II                4 (4%)                     13 (19%)
   G3                                     2 (2%)                     9 (9%)
   Age \> 70 lat                          37 (34%)                   23 (33%)

LUSI: lower uterine segment involvement.

###### 

3-, 5-, and 10-OS, DFS, and LRFS in treated and observed groups and among patients with low and medium risk of recurrence.

  ---------------------------------------------------------------------
  Groups and subgroups                                     
  ---------------------- ---------- --------- ----------- -------------
                         3-OS       5-OS      10-OS        

                                                          

  Treated                96,86%,    93%,      81,8%       NS

  versus                                                  

  Observed               100%       95,12%    93,3%       

  Treated                                                  

   Low risk              100%       100%      93,75%,     SS \
                                                          *p* = 0.018

   versus                                                 

   Medium risk           94,34%,    87,55%    72,01%      

  Observed                                                 

   Low risk              100%       100%      96,15%,     NS

  versus                                                  

   Medium risk           100%       90,95%    90,95%      

                                                          

                         3 - DFS    5 -DFS    10 - DFS     

                                                          

  Treated                96,74%,    95,58%,   95,58%,     NS

  versus                                                  

  Observed               97,14%,    93,98%    89,7%.      

  Treated                                                  

   Low risk              100%       97,5%     97,5%       NS

   versus                                                 

   Medium risk           93,91%,    93,91%,   93,91%,     

  Observed                                                 

   Low risk              93,75%     93,75%    84,38%,     NS

   versus                                                 

   Medium risk           100%       94,02%,   94,02%,     

                                                          

                         3 - LRFS   5 -LRFS   10 - LRFS    

                                                          

  Treated                97,77%,    97,77%,   97,77%,     NS

  versus                                                  

  Observed               97,14%,    95,57%    91,75%.     

  Treated                                                  

   Low risk              100%       100%      100%        NS

   versus                                                 

   Medium risk           96%        96%       96%         

  Observed                                                 

   Low risk              93,75%     93,75%    84,38%,     NS

   versus                                                 

   Medium risk           100%       97,06%,   97,06%,     
  ---------------------------------------------------------------------

OS: overall survival, DFS: disease-free survival, LRFS: local relapse-free survival.

###### 

5-OS and 5-DFS in patients with risk factors.

  ------------------------------------------------------------------------------------------
                    5-OS      5-DFS                                                     
  ----------------- --------- -------- --------- -------- -------- ----------- -------- ----
  FIGO IA           88,71%,   NS       96,11%,   NS       97,35%   0.047       92,92%   NS

  FIGO IB           84,41%    90,00%   85,71%    100%,                                  

  No risk factors   95,65%    0.015    100%      NS       100%     NS          100%     NS

  1 risk factor     81,59%    88,14%   97,72%    92,14%                                 

  2 risk factors    66,66%    100%     92,96%    94,28%                                 

  Age \> 70         92,86%,   0.011    95,29%,   NS       98,27%   NS \        93,35%   NS
                                                                   *p* = 0.1            

  Age \< 70         77,81%    94,44%   89,87%    95,23%                                 
  ------------------------------------------------------------------------------------------

###### 

Fractionation schemes and survival parameters.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                         Fractional dose     Total dose      Survival parameters                                                                                                                     Follow-up
  ------------------------------ ------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------- -----------
  Sorbe et al. \[[@B12]\]        3--8 Gy/5 mm        18--24 Gy       LRR: 2,6%, DM: 1,3%,\                                                                                                                   \-
                                                                     VR: 1,2%                                                                                                                                

  Weiss et al. \[[@B13]\]        4,6--4,9 Gy/5 mm\   13,8--14,7 Gy   Pelvic relapse 5,7%, vaginal stump relapse 1,6%, local and distance relapse 2,5%, DM: 1,6%, 5-RFS 74% in MR group and 94% in HR group   25,6 m
                                 (7 Gy/surface)                                                                                                                                                              

  Chadha et al. \[[@B14]\]       7 Gy/5 mm           21 Gy           VR: 0%, 5-OS: 93%, 5-DFS: 87%                                                                                                           30 m

  Anderson et al. \[[@B10]\]     5 Gy/5 mm           15 Gy           Pelvic relapse 3%, vaginal relapse 1%, 5-OS 84%, 5-DFS 93%,                                                                             \-

  Alektiar et al. \[[@B15]\]     6-7 Gy/5 mm         18--21 Gy       5-OS 93%, 5-DFS 97%                                                                                                                     48 m

  McCloskey et al. \[[@B16]\]    7 Gy/5 mm           21 Gy           Local relapse 3,4%, vaginal relapse 1,1%, vaginal and pelvic relapse 1,1%, pelvic relapse 1,1%                                          52 m

  Ríos et al. \[[@B17]\]         4 Gy/5 mm           20 Gy           Vaginal stump relapse 0%, relapse in lower part of vagina 1,7%, DM 6,7%                                                                 46,7 m

  PORTEC-2 \[[@B26]\]            7 Gy/5 mm           21 Gy           5-VR: 1,8%, 5-LRR: 5,1%, 5-OS 84,8%, 5-DFS 82,7%                                                                                        45 m

  Lin et al. \[[@B18]\]          7 Gy/5 mm           21 Gy           5-OS 86%, 5-DFS 89%                                                                                                                     55 m

  Atahan et al. \[[@B19]\]       5,5 Gy/5 mm         27,5 Gy         VR: 1,6%, DM 3,2%, 5-OS 96%, 5-DFS 93%                                                                                                  48 m

  Solhjem et al. \[[@B11]\]      7 Gy/5 mm           21 Gy           No local relapses                                                                                                                       23 m

  Cengiz et al. \[[@B22]\]       7 Gy/5 mm           21 Gy           5-OS 85%, 5-DFS 92%, 5-LC 95%                                                                                                           54 m

  Rittenberg et al. \[[@B23]\]   5,6 Gy/5 mm         16,8 Gy         VR: 2,3% 2-OS 97%, 5-OS 95%                                                                                                             32 m

  Horowitz et al. \[[@B20]\]     7 Gy/5 mm           21 Gy           All relapse: 8,5%, vaginal relapses: 2%, 5-OS 87%, 5-DFS 90%                                                                            65 m

  Rovirosa et al. \[[@B24]\]     5-6 Gy/5 mm         20--24 Gy       No vaginal relapses                                                                                                                     75 m

  Rovirosa et al. \[[@B24]\]     4--6 Gy/5 mm        24--36 Gy       No vaginal relapses                                                                                                                     88 m

  Rovirosa et al. \[[@B25]\]     6 Gy/5 mm           18 Gy           No vaginal relapses                                                                                                                     41 m

  Townamchai et al. \[[@B21]\]   4 Gy/surface        24 Gy           Vaginal relapses 1,2%, para-aortic nodes relapses 1,9%, DM 1,2%                                                                         22,8 m
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LRR: locoregional relapses, DM: distal metastases, VR: vaginal recurrence, RFS: recurrence-free survival, MR: mediate risk, HR: high risk, m: months.
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